ATE537819T1 - Nutrazeutische zusammensetzungen zur behandlung von muskelschwund - Google Patents

Nutrazeutische zusammensetzungen zur behandlung von muskelschwund

Info

Publication number
ATE537819T1
ATE537819T1 AT06806182T AT06806182T ATE537819T1 AT E537819 T1 ATE537819 T1 AT E537819T1 AT 06806182 T AT06806182 T AT 06806182T AT 06806182 T AT06806182 T AT 06806182T AT E537819 T1 ATE537819 T1 AT E537819T1
Authority
AT
Austria
Prior art keywords
muscle wasting
treating muscle
nutraceutical compositions
muscle
nutraceutical
Prior art date
Application number
AT06806182T
Other languages
English (en)
Inventor
Daniel Raederstorff
Ying Wang-Schmidt
Swen Wolfram
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of ATE537819T1 publication Critical patent/ATE537819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06806182T 2005-10-14 2006-10-11 Nutrazeutische zusammensetzungen zur behandlung von muskelschwund ATE537819T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05022414 2005-10-14
EP06009943 2006-05-15
PCT/EP2006/009814 WO2007042271A2 (en) 2005-10-14 2006-10-11 Nutraceutical composition for the treatment of muscle wasting

Publications (1)

Publication Number Publication Date
ATE537819T1 true ATE537819T1 (de) 2012-01-15

Family

ID=37499262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06806182T ATE537819T1 (de) 2005-10-14 2006-10-11 Nutrazeutische zusammensetzungen zur behandlung von muskelschwund

Country Status (7)

Country Link
EP (1) EP1937232B1 (de)
JP (1) JP2009511522A (de)
KR (1) KR20080105023A (de)
CN (1) CN101978958A (de)
AT (1) ATE537819T1 (de)
ES (1) ES2379810T3 (de)
WO (1) WO2007042271A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006135A1 (en) * 2005-07-07 2007-01-18 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
WO2007049796A2 (en) * 2005-10-26 2007-05-03 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
WO2007112366A2 (en) * 2006-03-24 2007-10-04 Cella Charles H Animal product enrichment using resveratrol
KR101473017B1 (ko) 2006-07-05 2014-12-15 카오카부시키가이샤 노화 억제제
EP2170338A2 (de) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs zur modulierung von energieregulation und gehirnfunktion
EP2719379A1 (de) * 2008-04-17 2014-04-16 DSM IP Assets B.V. Hydroxytyrosol zur Unterstützung der Mitochondrien
WO2010118789A1 (en) * 2009-04-17 2010-10-21 Dsm Ip Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
JP5878016B2 (ja) * 2009-09-18 2016-03-08 株式会社明治 筋拘縮予防剤
WO2011041937A1 (en) * 2009-10-07 2011-04-14 Dsm Ip Assets, B.V. Use of hydroxytyrosol for improving muscle differentiation
WO2012036168A1 (ja) * 2010-09-14 2012-03-22 北海道公立大学法人札幌医科大学 筋ジストロフィーを処置するための組成物
ITMI20112093A1 (it) * 2011-11-17 2013-05-18 Lachifarma Srl Lab Chimico Farmaceutico Sa Composizioni comprendenti idrossitirosolo e epigallocatechin gallato
MX367861B (es) * 2012-10-04 2019-09-09 Abbott Lab Una composición nutricional para usarse en la preservación del músculo esquelético.
MX2015013000A (es) 2013-03-15 2015-12-01 Abbott Lab Metodos de mantenimiento y mejora de la funcion muscular.
SG10201800500UA (en) * 2013-08-09 2018-03-28 Suntory Holdings Ltd Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
WO2015094767A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for maintaining or increasing bodyweight using decaffeinated green tea extract
CN106061291A (zh) * 2013-12-18 2016-10-26 雅培公司 使用绿茶提取物来增加骨骼肌蛋白质合成的方法
BR112018007958B1 (pt) * 2015-11-17 2022-04-19 Société des Produits Nestlé S.A. Composições compreendendo polifenol, e uso não-terapêutico de oleuropeína.
WO2018224636A1 (en) * 2017-06-09 2018-12-13 Vib Vzw Glutamine dehydrogenase inhibitors for use in muscle regeneration
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
CN111315239A (zh) * 2017-11-21 2020-06-19 雀巢产品有限公司 针对肌肉质量和/或肌肉量使用橄榄苦苷或姜黄素的组合物和方法
CA3175049A1 (en) * 2020-03-10 2021-04-15 The Regents Of The University Of California Novel nutrients to enhance load-induced muscle hypertrophy
JP2026526559A (ja) * 2023-08-02 2026-08-07 アボット・ラボラトリーズ 骨格筋可動性及び／若しくは骨格筋量を維持すること並びに／又は骨格筋力の回復のための方法及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103211806B (zh) * 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 新颖的营养药物性组合物及其用途
WO2007006135A1 (en) * 2005-07-07 2007-01-18 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
WO2007020917A1 (ja) * 2005-08-18 2007-02-22 The University Of Tokushima ユートロフィン産生の増強持続剤とこれを用いる加工食品

Also Published As

Publication number Publication date
JP2009511522A (ja) 2009-03-19
EP1937232B1 (de) 2011-12-21
WO2007042271A2 (en) 2007-04-19
KR20080105023A (ko) 2008-12-03
WO2007042271A8 (en) 2008-08-28
WO2007042271A3 (en) 2008-02-14
EP1937232A2 (de) 2008-07-02
ES2379810T3 (es) 2012-05-03
CN101978958A (zh) 2011-02-23

Similar Documents

Publication Publication Date Title
WO2007042271A8 (en) Nutraceutical composition for the treatment of muscle wasting
BRPI0518334A2 (pt) composiÇço de revestimento, mÉtodo de revestimento, revestimento, e, mÉtodo para preparar uma composiÇço de revestimento
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
TW200612892A (en) Novel compounds
MX2009003911A (es) Formulaciones de liberacion inmediata, mejoradas de topiramato.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
DE602005025517D1 (de) Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
TW200732296A (en) Novel compounds
AR050717A1 (es) Composiciones farmaceuticas
TW200630336A (en) Novel compounds
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
TW200745003A (en) Novel compounds
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DOP2006000268A (es) Agentes antibacterianos
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.